178 related articles for article (PubMed ID: 34266395)
21. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
[TBL] [Abstract][Full Text] [Related]
22. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
[TBL] [Abstract][Full Text] [Related]
24. Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study.
Chinnadurai R; Flanagan E; Jayson GC; Kalra PA
BMC Nephrol; 2019 Oct; 20(1):380. PubMed ID: 31640599
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitors versus histamine-2 receptor blockers for stress ulcer prophylaxis in patients with sepsis: a retrospective cohort study.
Huang M; Han M; Han W; Kuang L
J Int Med Res; 2021 Jun; 49(6):3000605211025130. PubMed ID: 34182815
[TBL] [Abstract][Full Text] [Related]
26. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
Liew JW; Peloquin C; Tedeschi SK; Felson DT; Zhang Y; Choi HK; Terkeltaub R; Neogi T
Arthritis Care Res (Hoboken); 2022 Dec; 74(12):2059-2065. PubMed ID: 35245410
[TBL] [Abstract][Full Text] [Related]
27. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
28. CKD Progression and Mortality Among Men and Women: A Nationwide Study in Sweden.
Swartling O; Rydell H; Stendahl M; Segelmark M; Trolle Lagerros Y; Evans M
Am J Kidney Dis; 2021 Aug; 78(2):190-199.e1. PubMed ID: 33434591
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
Zhang L; Liu X; Pascoe EM; Badve SV; Boudville NC; Clayton PA; De Zoysa J; Hawley CM; Kanellis J; McDonald SP; Peh CA; Polkinghorne KR; Johnson DW
Nephrology (Carlton); 2016 May; 21(5):387-96. PubMed ID: 26393772
[TBL] [Abstract][Full Text] [Related]
30. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.
Liu P; McMenamin ÚC; Johnston BT; Murchie P; Iversen L; Lee AJ; Vissers PAJ; Cardwell CR
Br J Cancer; 2020 Jul; 123(2):307-315. PubMed ID: 32367073
[TBL] [Abstract][Full Text] [Related]
31. Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.
Hsu JY; Roy JA; Xie D; Yang W; Shou H; Anderson AH; Landis JR; Jepson C; Wolf M; Isakova T; Rahman M; Feldman HI;
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1181-1189. PubMed ID: 28242844
[TBL] [Abstract][Full Text] [Related]
32. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
33. Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
PLoS Med; 2016 Sep; 13(9):e1002128. PubMed ID: 27648564
[TBL] [Abstract][Full Text] [Related]
34. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
35. Progression and outcomes of non-dialysis dependent chronic kidney disease patients: A single center longitudinal follow-up study.
Khan YH; Sarriff A; Adnan AS; Khan AH; Mallhi TH; Jummaat F
Nephrology (Carlton); 2017 Jan; 22(1):25-34. PubMed ID: 26718476
[TBL] [Abstract][Full Text] [Related]
36. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
[TBL] [Abstract][Full Text] [Related]
37. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis.
Sun J; Sun H; Cui M; Sun Z; Li W; Wei J; Zhou S
Int Urol Nephrol; 2018 Oct; 50(10):1835-1843. PubMed ID: 29948864
[TBL] [Abstract][Full Text] [Related]
38. Gastric Acid Suppressant Prophylaxis in Pediatric Intensive Care: Current Practice as Reflected in a Large Administrative Database.
Costarino AT; Dai D; Feng R; Feudtner C; Guevara JP
Pediatr Crit Care Med; 2015 Sep; 16(7):605-12. PubMed ID: 25901549
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis.
Pérez-Fontan M; Machado Lopes D; García Enríquez A; López-Calviño B; López-Muñiz A; García Falcón T; Rodríguez-Carmona A
PLoS One; 2016; 11(2):e0148806. PubMed ID: 26872254
[TBL] [Abstract][Full Text] [Related]
40. Insignificant impact of VUR on the progression of CKD in children with CAKUT.
Ishikura K; Uemura O; Hamasaki Y; Nakai H; Ito S; Harada R; Hattori M; Ohashi Y; Tanaka R; Nakanishi K; Kaneko T; Iijima K; Honda M;
Pediatr Nephrol; 2016 Jan; 31(1):105-12. PubMed ID: 26404649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
